Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERINTA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Premenstrual dysphoric disorder
Prevention of pregnancy
50 mg orally twice daily
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic via CYP2D6 and CYP3A4; active metabolites include N-desmethylcitalopram.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98% bound to albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd = 0.5–0.8 L/kg, indicating distribution into total body water and some tissue binding.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 75–85% (first-pass metabolism reduces bioavailability from 90% to 75–85%).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 25 mg twice daily. GFR <30 m L/min: Not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 25 mg twice daily. Child-Pugh C: Not recommended.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in pediatric patients.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment; use caution due to increased risk of adverse effects.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Serotonin syndrome,QT prolongation,Hyponatremia,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide,Known hypersensitivity to cerinta
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Take with food to improve absorption and reduce GI side effects. Avoid grapefruit, grapefruit juice, and Seville oranges as they are strong CYP3A4 inhibitors and can increase ceritinib levels.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal renal dysfunction, and skull ossification delay.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Contraindicated. Cerinta excreted in human milk; M/P ratio not established. Potential for infant nephrotoxicity and phototoxicity.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; contraindicated. No safe dose established. Increased volume of distribution and renal clearance in pregnancy would likely require dose escalation if used, but risk outweighs benefit.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Cerinta (ceritinib) is a potent ALK inhibitor. Must monitor for GI toxicities (diarrhea, nausea, vomiting) and hepatotoxicity. Administer with food to reduce nausea. Avoid concurrent strong CYP3A4 inhibitors/inducers. Baseline and periodic LFTs, serum lipase, and glucose are required. May cause QTc prolongation; avoid in patients with baseline QTc >470 ms. Interstitial lung disease (ILD) is a rare but serious adverse effect; discontinue if ILD suspected.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take ceritinib exactly as prescribed, with food, at the same time each day.,Do not crush or split tablets; swallow whole.,Common side effects include diarrhea, nausea, vomiting, and abdominal pain; contact your doctor if severe or persistent.,Report any signs of liver problems (yellow skin/eyes, dark urine, severe fatigue) or pancreatitis (severe upper abdominal pain).,Avoid grapefruit juice, grapefruit, and Seville oranges during treatment.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,Women of childbearing age must use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medicine.,Monitor blood glucose levels regularly; report any symptoms of hyperglycemia (excessive thirst, frequent urination).,Avoid activities requiring alertness if you experience dizziness or fatigue.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERINTA vs ALYACEN 7/7/7, answered by our medical review team.
CERINTA is a Oral contraceptive that works by Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERINTA and ALYACEN 7/7/7 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERINTA is: 50 mg orally twice daily. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERINTA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERINTA is classified as Category C. Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal re. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.